- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07925476
EvoXRare AI-Assisted Interpretation of Emergency Chest Radiographs (CXR-AI-RCT)
EvoXRare-Assisted Chest Radiograph Interpretation in Emergency and Critically Ill Adults: A Nationwide Multicenter Randomized Controlled Trial
Chest radiography is widely used in emergency departments, resuscitation rooms, intensive care units, and other acute-care settings. Clinically important abnormalities may be missed because findings are subtle, uncommon, obscured by overlapping anatomy, or encountered under high workload. This pragmatic randomized trial evaluates whether EvoXRare, an artificial intelligence system that provides a draft chest radiograph report and high-risk alerts for uncommon or clinically important abnormalities, reduces clinically important diagnostic misses compared with routine physician interpretation alone. Approximately 70,000 adults will be randomized 1:1 across 15-20 hospitals in China. The primary endpoint is the patient-level rate of clinically important abnormalities present on the reference standard but not reported in the initial clinical interpretation. Key secondary outcomes include detection of rare or easily missed findings, time to recognition of critical abnormalities, report turnaround time, false-positive alerts, additional imaging, recall/communication events, and selected short-term clinical outcomes.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This is a nationwide, multicenter, prospective, parallel-group, superiority randomized controlled trial with individual participant-level 1:1 allocation and blinded central endpoint adjudication. Eligible participants are adults undergoing clinically indicated chest radiography in emergency or critical-care settings. Only one index radiograph encounter per participant contributes to the primary randomized analysis.
In the control arm, physicians interpret the chest radiograph using the participating hospital's usual workflow without access to EvoXRare trial output. In the intervention arm, EvoXRare processes the same image on an independent AI workstation and provides a pre-generated report and/or high-risk prompts. The physician must review the original image, verify or edit the AI output, and remains responsible for the final report and all clinical communication. Both arms retain routine senior review and local critical-result procedures.
The AI model version, weights, preprocessing, thresholds, supported finding set, and report format are frozen before formal enrollment. No online learning or outcome-driven recalibration occurs during the randomized trial. If AI processing fails or images do not meet technical requirements, clinical care proceeds without delay and the participant remains in the assigned group for intention-to-treat analysis.
The reference standard is established by a blinded adjudication process using the index radiograph together with clinically available follow-up information, which may include subsequent CT, ultrasound, pathology, surgery, laboratory findings, clinical course, discharge diagnosis, or follow-up imaging. Adjudicators do not use the randomized assignment or EvoXRare output when determining whether a prespecified abnormality was present on the index radiograph.
The trial is designed primarily to test clinical diagnostic performance and workflow impact, not to retrain the AI system. It specifically emphasizes uncommon, high-consequence, and easily missed chest radiograph findings while also evaluating overall report quality and efficiency.
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Xiaoyu Han, PhD
- Telefoonnummer: +86 18202771604
- E-mail: xiaoyuhan1123@163.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18 years or older.
- Undergoing a clinically indicated chest radiograph in a participating emergency department, resuscitation room, intensive care unit, or other prespecified acute/critical-care setting.
- Chest radiograph is technically accessible to the study workflow before or during routine clinical interpretation.
- The participant has not previously been randomized in this trial, unless the final protocol explicitly permits a separate recurrent-encounter analysis that does not enter the primary endpoint.
- Consent or ethics-approved waiver/alteration of consent is satisfied according to the activated site protocol.
Exclusion Criteria:
- Age younger than 18 years.
- Image is missing, corrupted, or technically non-diagnostic to a degree that prevents clinical interpretation.
- Radiograph was obtained solely for research rather than clinical care.
- AI processing cannot be initiated because the image format or transfer route is outside the locked system specification; such cases may be recorded in screening logs but are not randomized unless the protocol allows post-randomization technical failure.
- Prior randomization of the same participant in this trial for the primary participant-level analysis.
- Any local legal, ethical, or institutional restriction that prevents study participation or required data use.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: EvoXRare AI-Assisted Chest Radiograph Interpretation.
Usual chest radiograph interpretation plus access to EvoXRare-generated draft report and high-risk prompts. The physician reviews the original image, accepts/rejects/edits AI suggestions, submits the final report, and follows local critical-result communication procedures. |
EvoXRare is an artificial intelligence software system that analyzes chest radiographs and provides draft reports and high-risk prompts to the interpreting physician. The physician reviews the original images and AI outputs and accepts, rejects, or edits the suggestions before finalizing the radiology report. |
|
Geen tussenkomst: No Intervention / Active usual-care comparator: Standard Chest Radiograph Interpretation.
Routine physician interpretation according to the participating hospital's usual workflow, without access to EvoXRare trial output. Routine nontrial tools already in use may continue only if documented before site activation and applied consistently. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Patient-Level Clinically Important Abnormality Miss Rate on the Index Chest Radiograph
Tijdsspanne: From index radiograph interpretation through completion of blinded endpoint adjudication, using clinically available information obtained during the index encounter and prespecified follow-up window (target: within 30 days when available).
|
Proportion of randomized participants with at least one prespecified clinically important abnormality (Category A or B) judged present on the reference standard but absent from the initial finalized chest radiograph report produced under the assigned strategy. |
From index radiograph interpretation through completion of blinded endpoint adjudication, using clinically available information obtained during the index encounter and prespecified follow-up window (target: within 30 days when available).
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- WHUH-CXR-AI-RCT-2026-11
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Yes, through controlled access subject to compatible consent/ethics approval and institutional authorization.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- ANALYTIC_CODE
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .